Use of pharmacokinetic/pharmacodynamic (PKPD) modeling for starting dose selection in first-in-human trials with high-risk monoclonal antibodies.

被引：0
|
作者：
Agoram, B. M. [1 ]
Martin, S. W. [1 ]
Davis, J. [1 ]
机构：
[1] Pfizer Inc, Sandwich, Kent, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 21 条
  • [1] Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics
    Agoram, Balaji M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (02) : 153 - 160
  • [2] Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
    Muller, P. Y.
    Brennan, F. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (03) : 247 - 258
  • [3] Selection of first-in-human starting dose of anti-OX40 agonist monoclonal antibody BMS-986178 using a pharmacokinetic/pharmacodynamic-based approach
    Huang, Christine
    Feng, Yan
    Barnhart, Bryan
    Quigley, Michael
    Huber, John
    Bello, Akintunde
    Marathe, Punit
    Aanur, Praveen
    Reilly, Timothy
    Yang, Zheng
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [4] Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
    Marie Viala
    Marie Vinches
    Marie Alexandre
    Caroline Mollevi
    Anna Durigova
    Nadia Hayaoui
    Krisztian Homicsko
    Alice Cuenant
    Céline Gongora
    Luca Gianni
    Diego Tosi
    British Journal of Cancer, 2018, 118 : 679 - 697
  • [5] Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
    Viala, Marie
    Vinches, Marie
    Alexandre, Marie
    Mollevi, Caroline
    Durigova, Anna
    Hayaoui, Nadia
    Homicsko, Krisztian
    Cuenant, Alice
    Gongora, Celine
    Gianni, Luca
    Tosi, Diego
    BRITISH JOURNAL OF CANCER, 2018, 118 (05) : 679 - 697
  • [6] Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
    Suh, Hoon Young
    Peck, Carl C.
    Yu, Kyung-Sang
    Lee, Howard
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 4005 - 4016
  • [7] Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312)
    Pawaskar, Dipti
    Chen, Xi
    Glassman, Fiona
    May, Frauke
    Roberts, Anthony
    Biondo, Mark
    McKenzie, Andrew
    Nolte, Marc W.
    Jusko, William J.
    Tortorici, Michael
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 709 - 720
  • [8] Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection
    Pasquiers, Blaise
    Benamara, Salih
    Felices, Mathieu
    Nguyen, Laurent
    Decleves, Xavier
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [9] First-in-Human Dose Selection for a Novel Fusion Protein Using Animal Safety Data, Pharmacodynamics, and Pharmacokinetic Modeling
    Fortin, Marie C.
    Manca, Dino
    Gursahani, Hemamalini
    Lin, Tong
    Markova, Svetlana
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2023, 42 (01) : 89 - 89
  • [10] The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
    Muller, Patrick Y.
    Milton, Mark
    Lloyd, Peter
    Sims, Jennifer
    Brennan, Frank R.
    CURRENT OPINION IN BIOTECHNOLOGY, 2009, 20 (06) : 722 - 729
123